anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
The invention relates to a composition and method for the preparation of a medicamentous form based on 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-1-(1-piperazinyl)-quino lin-3-carboxylic acid monohydrochloride, known as (cyprophloxacine), which is applied as antibacterial medicine in the medical practice. The composition includes: cyprophloxacine hydrochloride monohydrate and lactose monohydrate in ratio 4.93:1, mannitol SD 200, microcrystalline cellulose, sodium glucolate starch, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when cyprofloxacine and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small balde, and 1500 r.p.m. for the large blade. Separately, the dissolved sodium gluconate starch is added at continuous agitation to the homogenized mixture. Granular mass is produced which is dried at 45-50oC to residual moisture of 3% and is calibrated. To the dry granular mass mannitol SD 200, microcrystalline cellulose, sodium glucolate starch, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when cyprofloxacin and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small blade, and 1500 r.p.m. for the large blade. Separately, the dissolved sodium gluconate starch is added at continuous agitation to the homogenized mixture. Granular mass is produced which is dried at 45-50oC to residual moisture of 3% and is calibrated. To the dry granular mass manitol SD 200, microcrystalline cellulose, colloidal silicon dioxide, talcum and mangensium stearate are added. The mixture produced is homogenized. A water impermeable layer of a film with Opadry is applied. 2 claims
PROBLEM TO BE SOLVED: To obtain a dermal disease treating agent for external use having less adverse effects such as a skin irritation and having a potent efficacy. SOLUTION: This dermal disease treating agent for external use, contains 1-99.8wt.% vitamin E, 0.9-99.8wt.% squalene as active ingredients. Further, 0.01-250 pts.wt. precutaneous absorption agent is blended based on 100 pts.wt. total of the vitamin E and squalene. The percutanepous absorption agent is selected from N-acylsarcosine (salt), a higher fatty acid ester of the reaction product of a 10-18C fatty acid with a 1-20C alcohol, a 2-10C dicarboxylic acid (salt), a hydroxycarboxylic acid ester of the reaction product of a 3-6C hydroxycarboxylic acid with a 1-20C alcohol and a fatty acid ethanol amide. The amount of a dose is such that it is applied to a lesion as an external agent by 0.01-10g daily as divided by one to several times.  It is effective for intractable dermal diseases such as atopic dermatitis, contact dermatitis, seborrheic dermatitis, Vidal lichen, eczema nummulare, eczema of housewives and solar dermatitis.
If at least one dose level of phase 1 is determined to be safe, the phase 2 dose expansion phase of the trial will be opened to enrollment. Subjects will receive the highest dose of CART 22-65s and huCART19 cells that were determined to be safe. 2 cohorts are planned: Cohort A (relapsed/refractory, CAR T cell naïve) \& Cohort B (prior treatment with a prior CAR T cell product).
A composition containing Ortilia secunda extracts is provided to show wrinkle and elasticity improvement by the Ortilia secunda extracts having effects of inhibiting type I collagenase and AP-1 and increasing generation of collagen while suppressing decomposition of the collagen. A composition for wrinkle improvement comprises Ortilia secunda extracts obtained by adding water and C1-C4 low alcohol such as ethanol and methanol or mixed solvents thereof. The Ortilia secunda extracts are active ingredients in the composition for wrinkle improvement. The Ortilia secunda extracts eliminate radicals. The composition has a formulation of external skin application. The composition for wrinkle improvement represents antioxidant.
The present invention relates to a traditional Chinese medicine, namely, granular powder for expelling blood stasis, which has the effects of activating blood circulation to dissipate blood stasis and promoting qi circulation to relieve pain and is used for treating internal blood stasis, headache or chest pain, internal heat, blurred vision with restlessness, insomnia, dreaminess, palpitation, severe palpitation, rashness, impatience and irascibility. The granular powder is prepared from 11 traditional Chinese medicines of peach seed, safflower, etc. as raw medicinal materials. The medicine also comprises 20 to 40 parts by weight of beta-cyclodextrin as a clathrating agent of volatile oil, 100 to 300 parts by weight of beta-cyclodextrin as a cosolvent of liposoluble constituents and 390 to 610 parts by weight of dextrin as a forming agent. In a preparation process, advanced methods of volatile oil extraction by the steam distillate extraction method, volatile oil clathration with the beta-cyclodextrin, spray-drying, dry-type granulation, etc. are adopted. The content and the stability of effective components are increased. A quality control method comprises the thin layer identification of angelica, hemlock parsley, platycodon root and radix glycyrrhiza; the high-efficient liquid phase method is used for measuring the content of paeoniflorin, ferulic acid and ligustilide. The medicine does not comprise processed honey and preservatives and has the advantages of safe administration, controllable quality and outstanding curative effects.
During a routine trabeculectomy surgery, a corneo-scleral block that includes TM tissue will be collected at the operating room. This tissue is routinely removed during every trabeculectomy surgery. The tissue will be stored immediately in normal saline at 4 degrees Celsius, and walked directly to the Jefferson Center for Translational Medicine at Thomas Jefferson University by the Wills eye glaucoma research fellow. TM tissue will be identified using light microscope base on TM cell pigmentation. The ocular tissue will be fixed and placed in pre-cooled fixative on ice for 1 hour. The lengths of mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having a side chain-linked amino acid. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nanoparticle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.
The invention provides a traditional Chinese medicine preparation for treating peptic ulcer, mainly gastric ulcer and duodenal ulcer. Due to the functional characteristics of strengthening the body resistance, removing the necrotic tissue and promoting tissue regeneration, the preparation can promote reversion and repair of pathological tissues, thereby solving the problem that clinically obstinate cases are short of a traditional Chinese medicine preparation with obvious curative effect. The preparation is prepared from 14 traditional Chinese medicines, namely ginseng, astragalus root, tuckahoe, bighead atractylodes rhizome, white peony root, hyacinth bletilla, angelica, immature bitter orange, amomum fruit, officinal magnolia bark, cinnamon, costus root, licorice and rhubarb. The preparation has the functions of dissipating blood stasis, removing the necrotic tissue, astringing ulcer, promoting tissue regeneration, invigorating qi and strengthening the body resistance. Based on different characteristics of each traditional Chinese medicine raw material, the preparation is prepared into granules by the steps of pretreatment such as volatilization, solvent extraction and the like, and then concentration, air drying and sterilization based on proportions and time. The traditional Chinese medicine preparation for treating peptic ulcer provided by the invention has the characteristics of obvious therapeutic effect, no adverse reaction and the like, and can be widely popularized in the field of traditional Chinese medicine clinic.
The safety and efficacy of multiple doses of adalimumab were assessed in adult patients with moderately to severely active Crohn's disease, CD, (Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450) in randomized, double-blind, placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted, and 79% of patients continued to receive at least one of these medications. 

Induction of clinical remission (defined as CDAI < 150) was evaluated in two studies. In Study CD-I, 299 TNF-blocker naïve patients were randomized to one of four treatment groups: the placebo group received placebo at Weeks 0 and 2, the 160/80 group received 160 mg adalimumab at Week 0 and 80 mg at Week 2, the 80/40 group received 80 mg at Week 0 and 40 mg at Week 2, and the 40/20 group received 40 mg at Week 0 and 20 mg at Week 2. Clinical results were assessed at Week 4. 

In the second induction study, Study CD-II, 325 patients who had lost response to, or were intolerant to, previous infliximab therapy were randomized to receive either 160 mg adalimumab at Week 0 and 80 mg at Week 2, or placebo at Weeks 0 and 2. Clinical results were assessed at Week 4. 

Maintenance of clinical remission was evaluated in Study CD-III. In this study, 854 patients with active disease received open-label adalimumab, 80 mg at week 0 and 40 mg at Week 2. Patients were then randomized at Week 4 to 40 mg adalimumab every other week, 40 mg adalimumab every week, or placebo. The total study duration was 56 weeks. Patients in clinical response (decrease in CDAI ≥70) at Week 4 were stratified and analyzed separately from those not in clinical response at Week 4. 

Induction of Clinical Remission

A greater percentage of the patients treated with 160/80 mg adalimumab achieved induction of clinical remission versus placebo at Week 4 regardless of whether the patients were TNF blocker naïve (CD-I), or had lost response to or were intolerant to infliximab (CD-II) (see Table 12). 

Maintenance of Clinical Remission

In Study CD-III at Week 4, 58% (499/854) of patients were in clinical response and were assessed in the primary analysis. At Weeks 26 and 56, greater proportions of patients who were in clinical response at Week 4 achieved clinical remission in the adalimumab 40 mg every other week maintenance group compared to patients in the placebo maintenance group (see Table 13). The group that received adalimumab therapy every week did not demonstrate significantly higher remission rates compared to the group that received adalimumab every other week. 

Of those in response at Week 4 who attained remission during the study, patients in the adalimumab every other week group maintained remission for a longer time than patients in the placebo maintenance group. Among patients who were not in response by Week 12, therapy continued beyond 12 weeks did not result in significantly more responses.
Liver fibrosis, an abnormal accumulation of collagen fibers in the liver, is caused due to several chronic liver diseases including viral hepatitis, alcoholic steatohepatitis, and metabolic dysfunction-associated steatohepatitis. Among the various symptoms of chronic hepatitis, liver fibrosis is the most crucial factor in determining patient prognosis. Extensive liver fibrosis leads to cirrhosis and liver cancer and shortens the lifespans of patients. However, no drug is currently approved for the treatment of liver fibrosis. Therefore, the identification of molecular mechanisms and druggable targets of liver fibrosis is urgently needed. Interleukin-11 is a member of the interleukin-6 family of inflammatory cytokines that is involved in multiple processes of inflammation and tissue repair. Recent reports also suggest the pro-fibrogenic function of interleukin-11 in various organs. In this study, we examined the fibrogenic potential of interleukin-11 in the liver using a choline-deficient, amino acid-defined high-fat diet, a mouse model of metabolic dysfunction-associated steatohepatitis that rapidly develops liver fibrosis. Although interleukin-11 was specifically upregulated in the liver in this pathological model, the loss of interleukin-11 signaling played minor roles in liver injury, inflammation, fibrosis, and signal transduction pathways. Our results indicate that the pro-fibrogenic function of interleukin-11 may vary among organs and disease etiologies.
LPS dose 2ng/kg. Imatinib 600mg 1 hour prior to LPS administration.
Patients randomized to the treatment arm will have a 25\[OH\] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25\[OH\] Vit D \>40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25\[OH\] Vit D levels are \<40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25\[OH\] Vit D level. At 3 months, if 25\[OH\] Vit D \>40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25\[OH\] Vit D \<40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25\[OH\] Vit D reaches a level \>40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25\[OH\] Vit D testing.
Growth promotion of animals and productive livestock comprises administering growth promoting amt. of quinoxaline-di-N-oxide carboxamide deriv. of formula (I) or its acid addition salt. In (I) R1 is H or 1-4C alkyl and R2 and R3 are each 1-4C alkyl or together with N atom form heterocyclic ring opt. substd. by 1-4C alkyl, the ring contains 4 or 5 C atoms and opt. O as further hetero atom; A is 1-4C alkylene. (I) are used to combat pathogenic microorganisms in veterinary medicine esp. effective in case of diseases of respiratory tract in poultry and infections of intestinal tract and urogenital system in domestic animals and livestock. They are also used as growth promoting agents. Administration can be perorally, via the abomasum or by injection.
Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRFi and CRF 2 ) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(IOkD)] was found to potentiates CRF-intracellular Ca 2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27kD)]. This interaction was CRFa-specific, as CRF1 responses were not potentiated by CRFBP(IOkD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(IOkD) was fused as a chimera with CRF 2a, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules. This resulted in the identification of negative allosteric modulators (NAMs) of the CRFBP(10kD)-CRF2 complex that blunt CRF-induced potentiation of /V-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission in dopamine neurons in the ventral tegmental area (VTA). These results provide the first evidence of specific roles for GRF 2 and CRFBP in the modulation of neuronal activity and suggest that NMDARs in the VTA may be a target for the treatment of stress and substance abuse disorders such as alcohol use disorder.
PURPOSE:To obtain a dental alloy having fine luster and causing no discoloration after application by adding Ga to an Ag-In alloy. CONSTITUTION:This dental alloy contains Ag and In as principal components and 0.01-10% Ga. Prescribed amounts of Ag, Pd and Ga are put in a crucible and melted by heating with an oxygen burner. The melt is charged into water to form granular Ag-Pd alloy. This alloy and prescribed amounts of In, Zn and Ga are put in a crucible and melted in an electric furnace kept at about 700 deg.C. The resulting melt is granulated by charging into water to obtain the desired alloy.
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting angiopoietin-like 3 (also known as ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions comprising ANGPTL3RNAi agents. Also disclosed are methods of using ANGPTL3RNAi agents and compositions. The ANGPTL3RNAi agents disclosed herein can be conjugated to a targeting ligand to facilitate delivery to cells, including hepatocytes. Pharmaceutical compositions are described that include one or more ANGPTL3RNAi agents, optionally with one or more additional therapeutic agents. In vivo delivery of ANGPTL3RNAi agents provides inhibition of ANGPTL3 gene expression, and may result in lower triglyceride and/or cholesterol levels in a subject. RNAi agents are useful in methods of treating ANGPTL 3-associated diseases and disorders, including cardiometabolic diseases, such as hypertriglyceridemia and hyperlipidemia.
PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.
This is an open-label (all people know the identity of the intervention), multi-center (conducted in more than one center), and exploratory study of single and repeat, escalating, intravenous (injection of a substance into a vein) doses of JNJ-17299425 in participants with traumatic brain injury. The study consists of 2 parts (Part 1 and Part 2), and each part will have 2 stages (Stage 1 and Stage 2). In Stage 1 of each part only standard care will be given, through sedation, analgesia and ventilation. If Intra cranial pressure (ICP) rises to greater than 20 millimeter of mercury (mmHG) after ventricular drainage, participants will enter Stage 2 of each part and will receive JNJ-17299425 (single dose in Part 1 and repeated dose in Part 2). During Part 1, safety and efficacy of JNJ-17299425 will be evaluated and during Part 2, safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses will be evaluated. Efficacy will primarily be evaluated by reduction in ICP. Blood samples will be collected for pharmacokinetic evaluation at pre and post administration of study treatment. Participants' safety will be monitored throughout the study.
The disclosure provides a file classification method and a platform, which belong to the technical field of data classification, and the method comprises the following steps: acquiring a preset multi-level classification category of a user, and determining phrase weights corresponding to the multi-level classification category based on a preset mapping relation. The phrase weight is the weight corresponding to each standard phrase. And obtaining a first file to be classified, extracting the phrases in the first file, and obtaining a plurality of first phrases. And converting the plurality of first phrases into a plurality of corresponding standard phrases to obtain a plurality of target standard phrases. And generating the feature vector of the first file based on the target standard phrase and the phrase weight. And inputting the feature vector of the first file into a pre-trained classifier to obtain a classification class corresponding to the first file. According to the file classification method, files with different contents can be automatically classified, different classification results are realized aiming at different level sequences, and therefore a more comprehensive and intelligent file classification effect is achieved.
Background: Systemic remedies such as cyclosporine, methotrexate, and retinoids are off-license treatment options that are considered for severe chronic hand eczema (CHE) that is resistant to first-line treatment. Objectives: The objective of this study was to determine the optimal treatment of CHE patients, including those with atopic Dermatitis®, and to compare the efficacy between cyclosporine and alitretinoin. Methods: This study was retrospective and included CHE patients who visited the Department of Dermatology at Hanyang University Seoul Hospital in Korea between March 2013 and February 2020. Results: A total of 95 CHE patients was included in this study. In the cyclosporine treatment group, there were more patients with severe baseline Investigator Global Assessment (IGA) (P = 0.033) and higher immunoglobulin E (IgE) level (P = 0.019). The mean recurrence duration was 15.9 weeks in the alitretinoin group and 22.9 weeks in the cyclosporine group, the difference between which was not statistically significant. In a subgroup analysis according to treatment drug, only the low IgE group showed a better recurrence profile for alitretinoin treatment compared to cyclosporine treatment (P = 0.039). When comparing the cumulative recurrence rate during the treatment period and subsequent follow-up periods, the cyclosporine group showed a greater incidence of recurrence than the alitretinoin group in all follow-up periods. The results of our study are consistent with the previously reported efficacy of alitretinoin. Despite the rapid response in the cyclosporine group, 12 weeks of CHE treatment with alitretinoin showed superior efficacy compared to cyclosporine treatment. Conclusions: Both alitretinoin and cyclosporine groups showed efficacy in patients with CHE. Cyclosporine is an alternative treatment of CHE that is refractory to alitretinoin or relapses after its use, especially in the presence of atopic Dermatitis®.